Skip to main content
Cellectis gains 2 CRISPR T-cell patents
2/14/2018

Two US patents were granted to Cellectis related to the invention of specific uses for RNA-guided endonucleases for T-cell gene editing, such as Cas9 or Cpf1.

Full Story: